Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma XenograftsGaspar J. Kitange, Jann N. Sarkaria, Gwen Lomberk et al.|Clinical Cancer Research|2012Cited by 151
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Kendra A. Porath et al.|Neuro-Oncology|2021Cited by 81
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastomaElizabeth C. Randall, Nathalie Y.R. Agar, Kristina B. Emdal et al.|Nature Communications|2018Cited by 79
Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft modelsAnn C. Mladek, Jann N. Sarkaria, Shiv K. Gupta et al.|Molecular Cancer Therapeutics|2019Cited by 3